Diagnostek of Albuquerque, NM, signed a definitive agreement lastmonth to be acquired by Medco Containment of Montvale, NJ. Medco'splans for Diagnostek's shared service MRI business are not clear,but the rationale for this merger was the complementarity
Diagnostek of Albuquerque, NM, signed a definitive agreement lastmonth to be acquired by Medco Containment of Montvale, NJ. Medco'splans for Diagnostek's shared service MRI business are not clear,but the rationale for this merger was the complementarity of thetwo firms' pharmacy lines. Diagnostek's imaging business doesnot appear to fit in as well to a merger of the two companies.
MRI services had become an increasingly small part of Diagnostek'srevenues over the past several years as it built up a large andprofitable mail-order pharmacy business (SCAN 2/28/90). The firmran a half dozen scanners, mostly high-field GE Signas and mostlyfor hospitals on a fee-per-scan basis.
Diagnostek had explored either selling its MRI systems or expandingfurther into the MRI center business and decided against bothoptions, according to Arthur C. Solomon, executive vice president.Solomon will continue with Medco as a senior executive followingthe merger.
High center prices, as well as the possibility of legislationrestricting referring-physician ownership more severely than currentfederal safe harbor guidelines, were factors mitigating againsta center buyout strategy.
"A year or so ago--because we have good financial resourcesand good (clinical) relationships--we looked at helping theselimited partnerships by coming in and doing buyouts," Solomontold SCAN. "We took a wait-and-see approach because of allthese states reacting with their own safe harbor provisions."
The 60/40 ownership guideline of the safe harbor regulationsallows for the maintenance of some physician participation. Withoutthis participation, the riskiness of most center deals is notworth the high multiples of earnings many physician owners areasking, he said.
Although Diagnostek has been approached by several potentialbuyers of its MRI business, no one offered a price high enoughto justify a sale, Solomon said. Potential buyers included sometrying to arrange rollups of multiple imaging facilities, he said.
"For the last two years we have had people calling uswanting to know what we want to do with (the MRI systems). Forus, the business has pretty much taken care of itself. They areprofitable. We have looked at the possibility of selling them,but no one came through with a deal we felt was more favorablethan holding on to them," Solomon said.
Breast MRI and Background Parenchymal Enhancement: What a Meta-Analysis Reveals
May 29th 2025Moderate or marked background parenchymal enhancement (BPE) reduces the sensitivity and specificity of MRI for breast cancer detection by more than 10 percent in comparison to scans with minimal or mild BPE, according to a new meta-analysis.
Lunit Unveils Enhanced AI-Powered CXR Software Update
May 28th 2025The Lunit Insight CXR4 update reportedly offers new features such as current-prior comparison of chest X-rays (CXRs), acute bone fracture detection and a 99.5 percent negative predictive value (NPV) for identifying normal CXRs.
Breast MRI and Background Parenchymal Enhancement: What a Meta-Analysis Reveals
May 29th 2025Moderate or marked background parenchymal enhancement (BPE) reduces the sensitivity and specificity of MRI for breast cancer detection by more than 10 percent in comparison to scans with minimal or mild BPE, according to a new meta-analysis.
Lunit Unveils Enhanced AI-Powered CXR Software Update
May 28th 2025The Lunit Insight CXR4 update reportedly offers new features such as current-prior comparison of chest X-rays (CXRs), acute bone fracture detection and a 99.5 percent negative predictive value (NPV) for identifying normal CXRs.
2 Commerce Drive
Cranbury, NJ 08512